Anas Younes: We are developing more than one drug for the same disease indication, so we can build future combination regimens

Anas Younes posted on LinkedIn:

”Our hematology team spent the last 3 days reviewing our disease strategy with external advisors. To make a bigger impact, we are developing more than one drug for the same disease indication, so we can build future combination regimens.

For that, we have to make choices and prioritize the combinations that are likely to be more impactful so we can accelerate their development plans. I am grateful to all who participated in these thorough reviews and discussions and shared their thoughts and ideas with our team.”

Source: Anas Younes/LinkedIn

Anas Younes is the Senior Vice President and Global Head of Hematology (Early and Late Stage) Oncology R&D at AstraZeneca. Prior to working for AstraZeneca, he was the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, and a Professor of Medicine at the University of Texas MD Anderson Cancer Center, Houston, TX.